Rituximab and intravenous immune globulin for desensitization during renal transplantation.

By A. Vo, M. Lukovsky, M. Toyoda, Jennifer P. Wang, N. Reinsmoen, Chih‐hung Lai, A. Peng, R. Villicana, S. Jordan. New England Journal of Medicine, 2008

628 citations recorded by the source corpus.

Subfields: Pharmacy, Public Health, Environmental and Occupational Health, Transplantation

View Paper: https://www.semanticscholar.org/paper/d3deffa80b7be7ca7c2c6dff58f7087b3c5df51e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Chadban
2. C. Ahn
3. D. Axelrod
4. B. Foster
5. Vijah Kher
6. Deepali Kumar
7. R. Oberbauer
8. J. Pascual

Citations in the corpus

• KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. (2020, background): “Desensitization with anti-B cell agents (eg, rituximab), proteasome inhibitors (eg, bortezomib), alone or in combination with other protocols, may increase transplant opportunities in the short term but, depending on antibody strength, can be associated with shortened longterm survival.(612,623,628,”